Fighting Resistance: Post-PARP Inhibitor Treatment Strategies in Ovarian Cancer

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2023 Mar 6

PMID 36872947

Authors

Ana C Veneziani

Clare Scott

Matthew J Wakefield

Anna V Tinker

Stephanie Lheureux

Affiliations

Soon will be listed here.

Abstract

Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of 'synthetic lethality' is exploited by PARPi in tumors with defects in DNA repair pathways, particularly homologous recombination deficiency. The use of PARPis has been increasing since its approval as maintenance therapy, particularly in the first-line setting. Therefore, resistance to PARPi is an emerging issue in clinical practice. It brings an urgent need to elucidate and identify the mechanisms of PARPi resistance. Ongoing studies address this challenge and investigate potential therapeutic strategies to prevent, overcome, or re-sensitize tumor cells to PARPi. This review aims to summarize the mechanisms of resistance to PARPi, discuss emerging strategies to treat patients post-PARPi progression, and discuss potential biomarkers of resistance.

Citing Articles

and Beyond: Impact on Therapeutic Choices Across Cancer.

Tan J, Zhang Z, Goh H, Ngeow J Cancers (Basel). 2025; 17(1.

PMID: 39796639 PMC: 11718952. DOI: 10.3390/cancers17010008.

Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review.

Dewani D, Jaiswal A, Karwade P Cureus. 2024; 16(9):e68463.

PMID: 39360040 PMC: 11446491. DOI: 10.7759/cureus.68463.

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer.

Kulkarni S, Gajjar K, Madhusudan S Front Oncol. 2024; 14:1414112.

PMID: 39135999 PMC: 11317305. DOI: 10.3389/fonc.2024.1414112.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.

Nesic K, Krais J, Wang Y, Vandenberg C, Patel P, Cai K Mol Cancer. 2024; 23(1):158.

PMID: 39103848 PMC: 11299415. DOI: 10.1186/s12943-024-02048-1.

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.

Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D Cell Death Dis. 2024; 15(7):521.

PMID: 39039067 PMC: 11263393. DOI: 10.1038/s41419-024-06894-1.

References

Parsels L, Karnak D, Parsels J, Zhang Q, Velez-Padilla J, Reichert Z . PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Mol Cancer Res. 2017; 16(2):222-232. PMC: 5805596. DOI: 10.1158/1541-7786.MCR-17-0455. View

Flynn M, Ledermann J . Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Cancer Drug Resist. 2022; 5(2):424-435. PMC: 9255242. DOI: 10.20517/cdr.2022.13. View

Rondinelli B, Gogola E, Yucel H, Duarte A, van de Ven M, van der Sluijs R . EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017; 19(11):1371-1378. DOI: 10.1038/ncb3626. View

Clements K, Schleicher E, Thakar T, Hale A, Dhoonmoon A, Tolman N . Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens. Nat Commun. 2020; 11(1):6118. PMC: 7704667. DOI: 10.1038/s41467-020-19961-w. View

Xu G, Chapman J, Brandsma I, Yuan J, Mistrik M, Bouwman P . REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015; 521(7553):541-544. PMC: 4671316. DOI: 10.1038/nature14328. View

Lawlor D, Martin P, Busschots S, Thery J, OLeary J, Hennessy B . PARP Inhibitors as P-glyoprotein Substrates. J Pharm Sci. 2014; 103(6):1913-20. DOI: 10.1002/jps.23952. View

Robert J, Jarry C . Multidrug resistance reversal agents. J Med Chem. 2003; 46(23):4805-17. DOI: 10.1021/jm030183a. View

Gadducci A, Cosio S, Landoni F, Lissoni A, Zola P, Laudani M . Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study. Anticancer Res. 2022; 42(4):2017-2022. DOI: 10.21873/anticanres.15681. View

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

10.

Karnitz L, Flatten K, Wagner J, Loegering D, Hackbarth J, Arlander S . Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol. 2005; 68(6):1636-44. DOI: 10.1124/mol.105.012716. View

11.

Wilson A, Stubbs M, Liu P, Ruggeri B, Khabele D . The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol Oncol. 2018; 149(3):575-584. PMC: 5986599. DOI: 10.1016/j.ygyno.2018.03.049. View

12.

Lloyd R, Wijnhoven P, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K . Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020; 39(25):4869-4883. PMC: 7299845. DOI: 10.1038/s41388-020-1328-y. View

13.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View

14.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte A, Lee J . Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016; 535(7612):382-7. PMC: 4959813. DOI: 10.1038/nature18325. View

15.

Mei L, Zhang J, He K, Zhang J . Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019; 12(1):43. PMC: 6482552. DOI: 10.1186/s13045-019-0733-6. View

16.

Nguyen L, Martens J, Van Hoeck A, Cuppen E . Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020; 11(1):5584. PMC: 7643118. DOI: 10.1038/s41467-020-19406-4. View

17.

Luserna di Rora A, Cerchione C, Martinelli G, Simonetti G . A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 2020; 13(1):126. PMC: 7507691. DOI: 10.1186/s13045-020-00959-2. View

18.

Stover E, Fuh K, Konstantinopoulos P, Matulonis U, Liu J . Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020; 159(3):887-898. DOI: 10.1016/j.ygyno.2020.09.029. View

19.

Munoz I, Jowsey P, Toth R, Rouse J . Phospho-epitope binding by the BRCT domains of hPTIP controls multiple aspects of the cellular response to DNA damage. Nucleic Acids Res. 2007; 35(16):5312-22. PMC: 2018624. DOI: 10.1093/nar/gkm493. View

20.

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J . PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017; 23(14):3711-3720. PMC: 5511572. DOI: 10.1158/1078-0432.CCR-16-3215. View